Xilio Therapeutics, Inc. (XLO)
NASDAQ · Healthcare
Xilio Therapeutics, Inc. Operating Income 2024–2025
Xilio Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2024 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Xilio Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -14.1 M, a 1.88% increase year-over-year.
- Xilio Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -44.3 M.
- Xilio Therapeutics, Inc. annual operating income for 2025 was -42.0 M, a 30.70% decrease from 2024.
- Xilio Therapeutics, Inc. annual operating income for 2024 was -60.6 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Xilio Therapeutics, Inc. Operating Income — FAQ
Xilio Therapeutics, Inc. (XLO) operating income over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
What is Xilio Therapeutics, Inc.'s operating income?
Xilio Therapeutics, Inc. (XLO) reported operating income of -$42M for fiscal 2025.
Where can I see XLO's operating income history?
The chart and table above show Xilio Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.